- Home
- KBR vs BBIO Comparison
KBR vs BBIO Comparison
Compare KBR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- BBIO
- Stock Information
- Founded
- KBR 1901
- BBIO 2015
- Country
- KBR United States
- BBIO United States
- Employees
- KBR N/A
- BBIO N/A
- Industry
- KBR Military/Government/Technical
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- BBIO Health Care
- Exchange
- KBR Nasdaq
- BBIO Nasdaq
- Market Cap
- KBR 6.3B
- BBIO 6.7B
- IPO Year
- KBR 2006
- BBIO 2019
- Fundamental
- Price
- KBR $55.20
- BBIO $34.17
- Analyst Decision
- KBR Strong Buy
- BBIO Strong Buy
- Analyst Count
- KBR 8
- BBIO 12
- Target Price
- KBR $70.75
- BBIO $57.09
- AVG Volume (30 Days)
- KBR 1.4M
- BBIO 3.1M
- Earning Date
- KBR 05-06-2025
- BBIO 04-29-2025
- Dividend Yield
- KBR 1.20%
- BBIO N/A
- EPS Growth
- KBR N/A
- BBIO N/A
- EPS
- KBR 2.98
- BBIO N/A
- Revenue
- KBR $7,979,000,000.00
- BBIO $127,415,000.00
- Revenue This Year
- KBR $15.78
- BBIO $13.67
- Revenue Next Year
- KBR $9.47
- BBIO $118.02
- P/E Ratio
- KBR $18.53
- BBIO N/A
- Revenue Growth
- KBR 12.84
- BBIO N/A
- 52 Week Low
- KBR $43.89
- BBIO $21.62
- 52 Week High
- KBR $72.60
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- KBR 65.10
- BBIO 44.19
- Support Level
- KBR $50.63
- BBIO $33.92
- Resistance Level
- KBR $55.80
- BBIO $39.16
- Average True Range (ATR)
- KBR 1.55
- BBIO 1.50
- MACD
- KBR 0.33
- BBIO -0.24
- Stochastic Oscillator
- KBR 89.07
- BBIO 10.35
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.